Similar to postnatal microarray studies, the use of prenatal microarray analysis has resulted in a significant increase in the identification of genomic alterations.
In recent years, microarray-based technology has resulted in the identification of breast cancer molecular subtypes (luminal, HER2-like, basal/triple negative) and gene-expression prognostic signatures (Van't Veer et al, 2002; Sorlie et al, 2003; Paik et al, 2006).
In recent years, microarray-based technology has resulted in the identification of clinically relevant molecular subtypes of breast cancer, providing insights into the molecular heterogeneity of the disease (Perou et al, 2000; Sorlie et al, 2003).
Over the past decade, microarray technologies have resulted in a paradigm shift in modern biology.
No change in gene expression measured by microarray may have resulted from non-responding oligos.
The difference in expression of the UGTs between the EST and microarray datasets might have resulted from the differences in the number of tissue types, size of each dataset and varieties used for data generation.
The constant evolution of microarrays has thus resulted in a significant hindrance to their power as a research or diagnostic tool by dividing datasets according to platform and seemingly limiting their interarray comparability.
Advancements in measurement techniques and computing methodologies have resulted in the use of microarray data in application to genetics, medicine, and patient diagnosis.
* An older genotyping technology, microarrays, has been employed at greater volume by labs such as 23andme.
